

2003051992
28/08/03

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

REVISED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 2002/074767 A1

(51) International Patent Classification⁷: C07D 403/12,
403/14, 401/12, 233/78, A61K 31/4166, 31/4439, 31/454,
A61P 35/00

(21) International Application Number:
PCT/SE2002/000472

(22) International Filing Date: 13 March 2002 (13.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0100902-6 15 March 2001 (15.03.2001) SE

(71) Applicant (for all designated States except US): AS-
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ERIKSSON, An-
ders [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund
(SE). LEPISTÖ, Matti [SE/SE]; AstraZeneca R & D
Lund, S-221 87 Lund (SE). LUNDKVIST, Michael
[SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE).
MUNCK AF ROSENSCHÖLD, Magnus [SE/SE];
AstraZeneca R & D Lund, S-221 87 Lund (SE). ZLA-
TOIDSKY, Pavol [SK/SE]; AstraZeneca R & D Lund,
S-221 87 Lund (SE).

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; As-
traZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS,
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI,
CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only
- of inventorship (Rule 4.17(iv)) for US only
- of inventorship (Rule 4.17(iv)) for US only
- of inventorship (Rule 4.17(iv)) for US only
- of inventorship (Rule 4.17(iv)) for US only

Published:


- with international search report

(88) Date of publication of the revised international search
report: 22 April 2004

[Continued on next page]

WO 2002/074767 A1

(54) Title: METALLOPROTEINASE INHIBITORS



(57) Abstract: Compounds of the
formula (I) wherein z is SO₂ or SO,
useful as metalloproteinase inhibitors,
especially as inhibitors of MMP12.



ACTION



162162

(15) Information about Correction:

see PCT Gazette No. 17/2004 of 22 April 2004, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.